By Deena Beasley June 3 (Reuters) - Cathy Smithwick, now 67, has lived with breast cancer, and then ovarian cancer, for more ...

An expert discusses how long-term safety considerations are evaluated through clinical trial data and postmarketing surveillance, emphasizing the importance of reporting unexpected adverse events to ...

Many cancers can be treated by administering DNA-damaging agents, such as platinum-based chemotherapy, because the resulting ...

New research by Wistar Institute scientists shows how targeting a cleft in the retinoblastoma protein can kill tumor-protecting macrophages in ovarian cancer. The discovery provides a novel ...

The immune system is comprised of two separate active arms of immunity to provide robust protection against disease. The two separate systems of immunity include the innate and adaptive immune ...

Recent findings published in Scientific Reports highlight a promising target for ovarian cancer drug development, emphasizing the importance of Claudin-4 in tumor progression and resistance. The study ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered a way that ovarian cancer tumors manipulate their environment to resist immunotherapy and identified a drug target that could ...

While we tend to quickly forget having been ill or having received a vaccine, the immune system remembers remarkably well. It has memory B cells—"trained" immune cells that circulate throughout the ...

BioInvent International AB (publ) ( BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors May 27, 2026 8:00 AM EDT Good morning, and welcome to the BioInvent ...

Here are some of the key gynecologic cancer presentations to watch at ASCO 2026.

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property ...